Sun, Xiaotian
Angelastro, James M.
Merino, David
Zhou, Qing
Siegelin, Markus D.
Greene, Lloyd A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS083795)
Sapience Therapeutics: Sponsored Research (no grant ref number) Thompson Family Foundation Initiative at Columbia University
Article History
Received: 22 January 2019
Revised: 22 July 2019
Accepted: 8 August 2019
First Online: 24 September 2019
Conflict of interest
: L.A.G. and J.M.A. are listed as co-inventors on a patent entitled “Methods for promoting apoptosis and treating tumor cells by inhibiting the expression or function of the transcription factor ATF5” which is owned by Columbia University and on patent “Compositions and Methods for Inhibiting Tumor Cells by Inhibiting the Transcription Factor ATF5,” which is owned by Columbia University and University of California, Davis. L.A.G. and J.M.A. were compensated scientific advisory board members of Sapience Therapeutics which has licensed dn-ATF5 technology from Columbia University. Columbia University holds equity in Sapience Therapeutics. No potential conflicts of interest were disclosed by the other authors.